TY - JOUR
T1 - Natural killer cells in intracranial neoplasms
T2 - Presence and therapeutic efficacy against brain tumours
AU - Kmiecik, Justyna
AU - Zimmer, Jacques
AU - Chekenya, Martha
N1 - Funding Information:
Acknowledgments We thank The Bergen Medical Research Foundation, The Norwegian Cancer Society, The Meltzer Fond, and The Norwegian Research Council FRIFORSK for supporting our research.
PY - 2014/1
Y1 - 2014/1
N2 - Natural killer (NK) cells are lymphocytes that play an important role in anti-tumour immunity. Their potential against brain cancer has been demonstrated in vitro and in vivo, both as a direct anti-tumour agent and in experimental therapies stimulating endogenous NK cell cytotoxicity. However, the clinical translation of these promising results requires detailed knowledge about the immune status of brain tumour patients, with focus on the NK cell population. In this report, we provide an overview of the studies investigating NK cell infiltration into the tumour, emphasizing the need of revision of the methodologies and further research in this field. We also discuss the potential of using autologous or allogeneic NK cells as effector cells in cellular therapy against brain cancer and developing immunotherapies stimulating endogenous NK cell-mediated anti-tumour response, such as blocking inhibitory killer immunoglobulin-like receptors. Combination of NK cell adoptive transfer with targeted therapies, such as anti-EGFR therapeutic antibody (CetuximAb) could also be a potent strategy.
AB - Natural killer (NK) cells are lymphocytes that play an important role in anti-tumour immunity. Their potential against brain cancer has been demonstrated in vitro and in vivo, both as a direct anti-tumour agent and in experimental therapies stimulating endogenous NK cell cytotoxicity. However, the clinical translation of these promising results requires detailed knowledge about the immune status of brain tumour patients, with focus on the NK cell population. In this report, we provide an overview of the studies investigating NK cell infiltration into the tumour, emphasizing the need of revision of the methodologies and further research in this field. We also discuss the potential of using autologous or allogeneic NK cells as effector cells in cellular therapy against brain cancer and developing immunotherapies stimulating endogenous NK cell-mediated anti-tumour response, such as blocking inhibitory killer immunoglobulin-like receptors. Combination of NK cell adoptive transfer with targeted therapies, such as anti-EGFR therapeutic antibody (CetuximAb) could also be a potent strategy.
KW - Brain tumour
KW - Immunotherapy
KW - NK cells
KW - Prognosis
KW - Tumour infiltrating lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=84891750270&partnerID=8YFLogxK
U2 - 10.1007/s11060-013-1265-5
DO - 10.1007/s11060-013-1265-5
M3 - Review article
C2 - 24085644
AN - SCOPUS:84891750270
SN - 0167-594X
VL - 116
SP - 1
EP - 9
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 1
ER -